Loading…
Loading…
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair.
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON and PHILADELPHIA, June 01, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today released updated Phase 1a/1b and pharmacokinetics (PK), safety, toxicity and preliminary efficacy data with faridoxorubicin (AVA6000, pre|CISION®-enabled doxorubicin) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Christina Coughlin, CEO of Avacta, commented: "Today's data further underscores our confidence in both our Gen One product faridoxorubicin (AVA6000) and our pre|CISION ® technology to significantly improve treatment options for cancer patients.
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event.
Avacta Group Plc (OTCMKTS:AVCTF - Get Free Report) shares dropped 5.3% on Friday. The company traded as low as $0.8151 and last traded at $0.8151. Approximately 4,000 shares were traded during mid-day trading, a decline of 37% from the average daily volume of 6,379 shares. The stock had previously closed at $0.8611. Avacta Group
Avacta Group Plc (AVCTF) Discusses Initial Faridoxorubicin Phase Ib Data and Safety Profile in Salivary Gland Cancer Transcript
Avacta Group Plc (OTCMKTS:AVCTF - Get Free Report) shares were up 1.2% during mid-day trading on Thursday. The stock traded as high as $0.98 and last traded at $0.98. Approximately 200 shares changed hands during trading, a decline of 96% from the average daily volume of 5,616 shares. The stock had previously closed at
No recent filings indexed.